The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 164:525, March 2007
doi: 10.1176/appi.ajp.164.3.525
© 2007 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BALHARA, Y.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BALHARA, Y.
Related Collections
* DSM

Letter to the Editor

Catatonia or No Catatonia: Still Beyond Lorazepam/Amobarbital

YATAN BALHARA, M.D.
New Delhi, India

To The Editor: Max Fink, M.D., and Michael Alan Taylor, M.D., have put forward a strong case in favor of making catatonia a separate category in subsequent editions of the DSM. However, their assertion that the diagnosis of catatonia should be made by observing the patient’s response to the administration of lorazepam/amobarbital seems to be an oversimplification of the issue. It is correct that catatonic features have been shown to respond to the administration of these compounds. However, the assumption that "[t]he diagnosis may be confirmed by symptomatic improvement after the acute administration of a challenge dose of lorazepam or amobarbital" (1, p. 1875) seems to be an overgeneralization. Response to these agents by no means provides a definitive diagnosis of catatonia, and there is no evidence to support the use of these tests as confirmatory. Catatonic features are not specific to any one condition and can be observed in a variety of conditions. Some of these conditions might respond to lorazepam or amobarbital; for example, conversion disorders such as conversion mutism are associated with features that do resemble catatonia and do respond to the amobarbital assisted interview. In summary, it may be prudent to avoid the use of response to lorazepam/amobarbital as a confirmatory test for the presence of catatonia.

Footnotes

Dr. Balhara reports no competing interests.

Reference

  1. Fink M, Taylor MA: Catatonia: subtype of syndrome DSM (editorial). Am J Psychiatry 2006; 163:1875–1876[Free Full Text]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BALHARA, Y.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BALHARA, Y.
Related Collections
* DSM


Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org